Iovance Biotherapeutics vs Moderna
Iovance Biotherapeutics (IOVA) and Moderna (MRNA) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $3.19B
- Last close
- $6.90
- 12 months
- +216.5%
- Market value
- $78.9B
- Last close
- $195.00
- 12 months
- +772.1%
At a glance
- The biggest part of Iovance Biotherapeutics's revenue is Amtagvi (83%); at Moderna it is Net product sales (94%).
- Iovance Biotherapeutics earns 98% of its revenue in the United States, Moderna 62%.
- By market value, Moderna ($78.9B) is about 25 times Iovance Biotherapeutics ($3.2B).
- Over the last 12 months Iovance Biotherapeutics's share price moved +216.5% and Moderna's +772.1%; against the S&P 500 that is +210.8 points and +766.4 points.
- In their last fiscal years Iovance Biotherapeutics kept -148.4% of revenue as net income and Moderna -145.2%.
- In the last 90 days insiders reported 0 open-market purchases at Iovance Biotherapeutics and 0 at Moderna; members of Congress disclosed 0 trades in Iovance Biotherapeutics and 4 in Moderna.
- Next results: Iovance Biotherapeutics Feb 22, 2027, Moderna Feb 11, 2027.
How each one makes money: Iovance Biotherapeutics revenue · Moderna revenue
Share prices on one chart
Iovance Biotherapeutics and Moderna, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Iovance Biotherapeutics IOVANASDAQ · Biological Products, (No Diagnostic Substances) | Moderna MRNANASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $3.19B | $78.9B |
| Revenue, last fiscal year | $264M | $1.94B |
| Net income, last fiscal year | −$391M | −$2.82B |
| Net marginNet income as a share of revenue | -148.4% | -145.2% |
| Free cash flow | ||
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Moderna against
Common questions
How is Iovance Biotherapeutics different from Moderna?
Iovance Biotherapeutics (IOVA) is in Biological Products, (No Diagnostic Substances) on NASDAQ, with $264M of revenue in its last fiscal year and a net margin of -148.4%. Moderna (MRNA) is in Biotechnology on NASDAQ, with $1.94B of revenue in its last fiscal year and a net margin of -145.2%. The biggest part of Iovance Biotherapeutics's revenue is Amtagvi (83%); at Moderna it is Net product sales (94%). Iovance Biotherapeutics earns 98% of its revenue in the United States, Moderna 62%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Iovance Biotherapeutics and Moderna compare in size?
Moderna has the larger market value: Iovance Biotherapeutics $3.19B and Moderna $78.9B, at the last close.
Whose share price rose more over the last 12 months, IOVA or MRNA?
Over the last 12 months Iovance Biotherapeutics moved +216.5% and Moderna +772.1%. Past price moves say nothing about the future.
Which has had more insider buying, Iovance Biotherapeutics or Moderna?
Since 2006, Iovance Biotherapeutics insiders reported 31 open-market purchases against 4 for Moderna. These are counts of what was filed, not a view on either stock.
Do members of Congress trade IOVA or MRNA?
In the last 12 months, members of Congress disclosed 0 trades in Iovance Biotherapeutics (IOVA) and 4 in Moderna (MRNA).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Iovance Biotherapeutics pageModerna pageRare insider trades this weekAll comparisons
https://oqro.io/compare/iova-vs-mrna







